Fc-Silenced Anti-CD40 Antibodies for Hidradenitis Suppurativa
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an unmet need for systemic therapies that effectively reduce inflammation in hidradenitis suppurativa (HS) while having a favorable safety profile, as current treatments like adalimumab are associated with increased safety risks and irreversible fibrosis.
Innovation Solution
The use of CD40 antagonists, particularly anti-CD40 antibodies with silenced ADCC activity, such as CFZ533, to inhibit CD40-CD40L signaling, administered through a loading and maintenance dosing regimen to achieve therapeutic plasma concentrations, targeting macrophages and B-cells in HS lesions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If adalimumab (TNF-α blockade) is used to treat HS, then inflammation is reduced, but safety risks increase (serious infections, malignancies)
Solution Approach 1:
The patent extracts the harmful Fc effector functions (ADCC, CDC) from the anti-CD40 antibody by introducing Fc-silencing mutations (N297A, L234A, L235A). This allows the antibody to block CD40-CD40L signaling and reduce inflammation while eliminating the risk of B-cell depletion and associated safety concerns, thus resolving the contradiction between therapeutic efficacy and safety
Solution Approach 2:
The patent changes the molecular parameters of the antibody Fc region by introducing specific amino acid mutations that alter its binding properties. The N297A mutation removes N-glycosylation sites, while L234A and L235A mutations prevent FcγR binding, thereby silencing effector functions while preserving target engagement and anti-inflammatory effects
2Object-affected harmful factors
If chronic antibiotic treatment is used for HS, then inflammatory lesions are treated, but irreversible fibrosis and scarring occur
Solution Approach 1:
The patent applies preliminary action by blocking the CD40-CD40L signaling pathway before irreversible fibrosis can develop. By preventing the inflammatory cascade at its upstream activation point through anti-CD40 antibody treatment, the therapy stops the progression from acute inflammation to chronic fibrotic changes, thereby treating inflammatory lesions while preventing scarring
3Ease of operation
If surgery is performed to reduce fibrotic tissue, then functionality is improved, but the disease progresses and requires repeated interventions
Solution Approach 1:
The patent applies preliminary action by systematically blocking the inflammatory pathway that drives disease progression. By continuously inhibiting CD40-CD40L signaling, the therapy prevents new inflammatory lesions and stops disease progression, thereby preserving tissue integrity and reducing the need for repeated surgical interventions to maintain functionality
Data Source
AI summary
The disclosure relates to methods, treatment regimens, uses, kits and therapies for treating hidradenitis suppurativa, by employing CD40 antagonists, such as anti-CD40 antibodies.